https://biobizbuzz.com/

BioBiz Buzz

News EN ↓ Odcinki: 28

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimer https://biobizbuzz.com/disclaimer/

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: biobizbuzz.com

Autor

https://biobizbuzz.com/

Kategoria

News

Strona podcastu

biobizbuzz.com

Ostatni odcinek

17 cze 2026

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Zainstaluj za darmo Android 5 mln+ pobrań · ocena 4,8 iOS niedługo

Odcinki

2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment 02.05.2025 14:23

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and...

3. Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation 02.05.2025 23:29

In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmona...

1. CRISPR Unleashed: How Caszyme Is Redefining the Future of Gene Editing 01.05.2025 19:54

This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology. Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sus...